迪高替尼软膏的购买渠道有哪些？

Digotinib ointment is the world's first approved external JAK inhibitor. Its purchase channels are limited by the launch progress and regional regulatory policies. Patients need to obtain drugs through compliant channels to avoid legal risks and hidden efficacy risks caused by illegal procurement. At present, the drug has not yet been fully launched in mainland China, and treatment needs need to be met through cross-border drug purchase, clinical trial participation or overseas drug purchase.

What are the purchasing channels for Digotinib Ointment?

Obtaining it must strictly comply with drug regulatory requirements. Patients must choose a purchasing plan based on drug accessibility, price sensitivity and urgency of treatment.

Japanese official channels

Corectim® Digotinib Ointment (0.5% concentration) produced by Japan's Torii Pharmaceuticals was approved by PMDA for marketing in 2020 and is used for patients over 16 years old with mild to moderate atopic dermatitis. Patients can purchase it through Japanese drug stores or online pharmacies, and an overseas prescription is required.

Cross-border drug purchase platforms

Some international cross-border drug purchase platforms provide overseas drug purchase services for Digotinib Ointment. Cross-border drug purchases are subject to partial value-added tax, and a single purchase must not exceed 3 months' supply.

Clinical trial participation

A domestic clinical trial for chronic hand eczema is recruiting patients. Selected patients can receive Digotinib cream (20mg/g concentration) and professional medical follow-up for free. However, it should be noted that clinical trial drugs are only for use by subjects and are not allowed to be resold or used for non-experimental purposes.

Quantity of Digotinib Ointment

The preparation quantity of Digotinib Ointment needs to be comprehensively evaluated based on the treatment cycle, drug specifications and storage conditions to avoid affecting the efficacy due to expired or insufficient drugs.

Dosage for a single course of treatment

According to the instructions approved by Japan PMDA, adult patients need to apply 0.5% ointment twice a day, and the single dosage should not exceed 5g. Based on the 15g specification, a single ointment can be used for 3 days. For patients with moderate to severe atopic dermatitis, 10 ointments are required for a 4-week course of treatment. Pediatric patients (under 14 years old) need to use the 0.25% concentration version, the dosage is reduced by half, but the treatment period may be extended to 8 weeks.

Storage Condition Restrictions

Should be stored at room temperature (usually 15~25℃), away from direct sunlight and high temperature and humid environments. If the patient's place of residence does not have a stable storage environment, it is recommended that the amount of medicine prepared at a time should not exceed 1 month's dosage.

Digotinib ointment treatment course

The treatment course of Digotinib ointment needs to be designed based on the disease type, severity and individual patient differences. The treatment cycle may last from several months to a year.

Atopic dermatitis treatment course

For adults with mild to moderate atopic dermatitis, the Japanese PMDA recommends a 16-week treatment course. Treatment duration for pediatric patients may be extended to 24 weeks, requiring skin assessment every 2 weeks.

Chronic hand eczema treatment course

For moderate to severe chronic hand eczema, the European EMA-approved treatment course is 52 weeks. Patients need to conduct hand skin examinations every 4 weeks. If local irritation reactions (such as erythema, itching) occur, the dosage needs to be reduced to once a day.

The long-term safety data of Digotinib Ointment still needs to be accumulated. It is recommended that patients who take the drug for more than 12 weeks should have a liver function test every 3 months and avoid using it in combination with other immunosuppressants.